Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Giulino-Roth

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Blood Advances|October 26, 2020
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesHanna Scholze, Regan E Stephenson, Raymond Reynolds, et al.
Blood|March 12, 2020
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapyTanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, et al.
Oncoimmunology|December 15, 2018
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,<i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) modelYaya Chu, Sanghoon Lee, Tishi Shah, et al.
Blood Advances|March 10, 2023
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphomaChristopher J Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Stenberg cells reveals escape from NK cell recognition and an unfolded protein responseMikhail Roshal, Isabella Y Kong, Wikum Dinalankara, et al.
Blood Cancer Journal|April 22, 2026
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein responseMikhail Roshal, Isabella Y Kong, Wikum Dinalankara, et al.
Frontiers in Immunology|September 26, 2018
Increased Risk for Malignancies in 131 Affected <i>CTLA4</i> Mutation CarriersDavid Egg, Charlotte Schwab, Annemarie Gabrysch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid TumorsTimothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Blood|October 24, 2012
Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genesLisa Giulino-Roth, Kai Wang, Theresa Y MacDonald, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Blood Advances|October 26, 2020
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesHanna Scholze, Regan E Stephenson, Raymond Reynolds, et al.
Blood|March 12, 2020
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapyTanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, et al.
Oncoimmunology|December 15, 2018
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,<i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) modelYaya Chu, Sanghoon Lee, Tishi Shah, et al.
Blood Advances|March 10, 2023
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphomaChristopher J Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Stenberg cells reveals escape from NK cell recognition and an unfolded protein responseMikhail Roshal, Isabella Y Kong, Wikum Dinalankara, et al.
Blood Cancer Journal|April 22, 2026
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein responseMikhail Roshal, Isabella Y Kong, Wikum Dinalankara, et al.
Frontiers in Immunology|September 26, 2018
Increased Risk for Malignancies in 131 Affected <i>CTLA4</i> Mutation CarriersDavid Egg, Charlotte Schwab, Annemarie Gabrysch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid TumorsTimothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Blood|October 24, 2012
Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genesLisa Giulino-Roth, Kai Wang, Theresa Y MacDonald, et al.
Pageof 6